The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Advances in BPDCN research: novel agents, combination approaches & increased disease awareness
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses recent advances in blastic plasmacytoid dendritic cell neoplasm (BPDCN) research, highlighting three key areas of excitement: the FDA approval of pivekimab sunirine, combinatorial therapy approaches, and the increasing recognition of BPDCN’s complexity and variability in presentation. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
